| 3.1 -0.17 (-5.2%) | 03-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.01  |
1-year : | 4.69 |
| Resists | First : | 3.43 |
Second : | 4.01 |
| Pivot price | 2.96 |
|||
| Supports | First : | 2.5 | Second : | 2.07 |
| MAs | MA(5) : | 3.06 |
MA(20) : | 3.15 |
| MA(100) : | 4.32 |
MA(250) : | 6.01 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 47 |
D(3) : | 44.7 |
| RSI | RSI(14): 42.1 | |||
| 52-week | High : | 13 | Low : | 2.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PHXM ] has closed below upper band by 37.6%. Bollinger Bands are 2.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.1 - 3.12 | 3.12 - 3.13 |
| Low: | 3.06 - 3.08 | 3.08 - 3.1 |
| Close: | 3.07 - 3.1 | 3.1 - 3.12 |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Wed, 03 Apr 2024
LE POINT sur les changements de recommandations à Paris - Boursorama
Wed, 03 Apr 2024
Phaxiam Therapeutics : un analyste ajuste le curseur - Boursier.com
Wed, 20 Mar 2024
Phaxiam Therapeutics : dispose de financements jusqu'en septembre 2024 - Boursier.com
Mon, 11 Mar 2024
Phaxiam : retrait volontaire de ses ADS - Boursier.com
Wed, 21 Feb 2024
Phaxiam : judicieux ?... - Fortuneo
Mon, 18 Sep 2023
Phaxiam Therapeutics : 1 pour 10 - Boursier.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.51e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.469e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -209.8 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 655.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 5.7e+006 % |
| Gross Profit (p.s.) | -32.28 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.92 |
| Dividend | 0 |
| Forward Dividend | 2350 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|